Back to search results

Long-term Follow-up for ADP Adoptive Cell Therapy

This study is for people who have previously received ADP adoptive cell therapy. It's designed to check on your long-term safety and how well the treatment worked for up to 15 years after your last treatment. The main goal is to track any delayed side effects (adverse events) or serious side effects. You can join if you've had at least one dose of ADP adoptive cell therapy, completed a related study, or received the therapy through managed access. The study is currently enrolling 250 participants, but the overall status is unclear.

Study design
This is an interventional study planning to enroll 250 participants. It is a long-term follow-up study.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 15 years after their last adoptive cell therapy infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03391778

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Enrolling by Invitation
PHASE1All AgesInterventional
USWM CT, LLC
~250 participants
Updated 2026-08-11 on ClinicalTrials.gov
What's tested:ADP adoptive cell therapy

At a glance

Recruiting sites
0 of 24 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs)
Measured over 15 years post last treatment

Conditions

Neoplasms

Explore related trials

Neoplasm

Where it's being run

24 sites across 19 states
United Kingdom3
Maryland2
Pennsylvania2
Texas2
Georgia1
Michigan1
Missouri1
New York1

Study leadership

  • Michael Nathenson, MD · STUDY_DIRECTOR · USWM CT, LLC

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants who have received at least one dose of ADP adoptive cell therapy agent.
Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
The investigator is responsible for review of medical history.
Capable of giving signed informed consent.

What this trial measures

  • Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs)15 years post last treatment

    AEs will be collected.